74 related articles for article (PubMed ID: 32154149)
1. CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.
Nath B; Suvarna VR
Perspect Clin Res; 2020; 11(1):44-46. PubMed ID: 32154149
[No Abstract] [Full Text] [Related]
2. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
Chilton R
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):345-349. PubMed ID: 30736150
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
5. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Guthrie R
Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
[TBL] [Abstract][Full Text] [Related]
7. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
Patorno E; Gopalakrishnan C; Brodovicz KG; Meyers A; Bartels DB; Liu J; Kulldorff M; Schneeweiss S
Diabetes Obes Metab; 2019 Aug; 21(8):1824-1836. PubMed ID: 30941884
[TBL] [Abstract][Full Text] [Related]
11. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.
Siwy J; Klein T; Rosler M; von Eynatten M
Proteomics Clin Appl; 2019 Mar; 13(2):e1800144. PubMed ID: 30632692
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Lietzau G; Magni G; Kehr J; Yoshitake T; Candeias E; Duarte AI; Pettersson H; Skogsberg J; Abbracchio MP; Klein T; Nyström T; Ceruti S; Darsalia V; Patrone C
Neurobiol Aging; 2020 May; 89():12-23. PubMed ID: 32143981
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
[TBL] [Abstract][Full Text] [Related]
14. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA
Watada H; Sakamaki H; Yabe D; Yamamoto F; Murata T; Hanada K; Hirase T; Okamura T
Diabetes Ther; 2020 Aug; 11(8):1721-1734. PubMed ID: 32557283
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
Lietzau G; Davidsson W; Östenson CG; Chiazza F; Nathanson D; Pintana H; Skogsberg J; Klein T; Nyström T; Darsalia V; Patrone C
Acta Neuropathol Commun; 2018 Feb; 6(1):14. PubMed ID: 29471869
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
